Guidelines from the American Association of Clinical Endocrinology recommend considering GLP-1 receptor agonists (RAs) in combination with metformin for patients who have not reached their glycemic target. Research has shown that GLP-1 RAs are the most effective non-insulin agent in reducing hemoglobin A1c in patients with uncontrolled type 2 diabetes. Incretin-based therapy can also be considered in patients with contraindications to metformin, such as of renal dysfunction. Data have shown that incretin-based therapies can improve glycemic efficacy alone or in combination with other oral antidiabetic drugs.
Learn more about type 2 diabetes.
Medscape © 2022 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: Romesh Khardori, Anne L. Peters. Fast Five Quiz: Type 2 Diabetes Incretin-Based Therapy - Medscape - May 16, 2022.